Development of therapeutics and prevention of HTLV-1-associated myelopathy (HAM/TSP) using patient registry 'HAM-net'

Development of therapeutics and prevention of HTLV-1-associated myelopathy (HAM/TSP) using patient registry 'HAM-net' - HAM-net

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039930

Enrollment

1000

Registered

2020-04-01

Start date

2020-03-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HTLV-1-Associated-Myelopathy Tropical Spastic Paraparesis (HAM/TSP)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) HAM/TSP diagnosed (2) Patients signed the informed consent document

Exclusion criteria

Exclusion criteria: Patients considered unsuitable for participation in the study by the investigator.

Design outcomes

Primary

Measure	Time frame
Time to reach grade 6 measured by Osame's Motor Disability Score (OMDS)	—

Secondary

Measure	Time frame
Change of Osame's Motor Disability Score Mortality and cause of death EQ-5D-5L score Descriptive statistics of background information Correlation of treatment with prognosis Correlation of HTLV-1 provirus load, CSF CXCL10, neopterin, anti-HTLV-1 antibody levels with prognosis Change of bladder dysfunction severity Prevalence and incidence of complications	—

Countries

Japan

Contacts

Public ContactNaoko Yagishita

Secretariat of HAM-net None

info@hamtsp-net.com0120-868619

Outcome results